RS50397B - Farmaceutska smeša - Google Patents

Farmaceutska smeša

Info

Publication number
RS50397B
RS50397B YUP-50/03A YUP5003A RS50397B RS 50397 B RS50397 B RS 50397B YU P5003 A YUP5003 A YU P5003A RS 50397 B RS50397 B RS 50397B
Authority
RS
Serbia
Prior art keywords
pharmaceutical composition
derivatives
pharmaceutically acceptable
starch
colsvelam
Prior art date
Application number
YUP-50/03A
Other languages
English (en)
Inventor
Hans Lengsfeld
Pierre BARBIER
Paul Hadvary
Original Assignee
F. Hoffmann-La Roche Ag.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8169384&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS50397(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann-La Roche Ag., filed Critical F. Hoffmann-La Roche Ag.,
Publication of YU5003A publication Critical patent/YU5003A/sh
Publication of RS50397B publication Critical patent/RS50397B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Farmaceutska smeša koja sadrži orlistat i farmaceutski prihvatljiv sekvestrant žučnih kiselina odabran iz grupe koja se sastoji od holestiramina, kolestipola, kolesvelama, kolestimida, sevelamera, derivata celuloze i derivata dekstrana, skroba i derivata skroba i njihovih farmaceutski prihvatljivih soli. Prijava sadrži 3 nezavisnih i 28 zavisnih zahteva
YUP-50/03A 2000-07-28 2001-07-19 Farmaceutska smeša RS50397B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00116393 2000-07-28

Publications (2)

Publication Number Publication Date
YU5003A YU5003A (sh) 2006-01-16
RS50397B true RS50397B (sr) 2009-12-31

Family

ID=8169384

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-50/03A RS50397B (sr) 2000-07-28 2001-07-19 Farmaceutska smeša

Country Status (38)

Country Link
US (5) US6756364B2 (sr)
EP (1) EP1307264B1 (sr)
JP (2) JP4265911B2 (sr)
KR (1) KR100572785B1 (sr)
CN (1) CN100423715C (sr)
AR (1) AR033548A1 (sr)
AT (1) ATE279961T1 (sr)
AU (2) AU2001289699B2 (sr)
BR (1) BR0112799B1 (sr)
CA (1) CA2416901C (sr)
CZ (1) CZ302087B6 (sr)
DE (1) DE60106623T2 (sr)
EC (1) ECSP034450A (sr)
EG (1) EG24357A (sr)
ES (1) ES2230362T3 (sr)
GT (1) GT200100152A (sr)
HK (1) HK1058636A1 (sr)
HR (1) HRP20030029B1 (sr)
HU (1) HU229292B1 (sr)
IL (2) IL154008A0 (sr)
JO (1) JO2320B1 (sr)
MA (1) MA26937A1 (sr)
ME (1) ME00671B (sr)
MX (1) MXPA03000771A (sr)
MY (1) MY127247A (sr)
NO (1) NO330546B1 (sr)
NZ (1) NZ523684A (sr)
PA (1) PA8523201A1 (sr)
PE (1) PE20020336A1 (sr)
PL (1) PL204443B1 (sr)
PT (1) PT1307264E (sr)
RS (1) RS50397B (sr)
RU (1) RU2241462C2 (sr)
SI (1) SI1307264T1 (sr)
TW (1) TWI275395B (sr)
UY (1) UY26860A1 (sr)
WO (1) WO2002009815A2 (sr)
ZA (1) ZA200300456B (sr)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1307263T3 (da) * 2000-07-28 2005-08-22 Hoffmann La Roche Hidtil ukendt anvendelse af lipaseinhibitorer
EP1307264B1 (en) * 2000-07-28 2004-10-20 F. Hoffmann-La Roche Ag New pharmaceutical composition
US7033373B2 (en) 2000-11-03 2006-04-25 Satiety, Inc. Method and device for use in minimally invasive placement of space-occupying intragastric devices
US6558400B2 (en) 2001-05-30 2003-05-06 Satiety, Inc. Obesity treatment tools and methods
MXPA04010371A (es) * 2002-04-26 2005-02-03 Hoffmann La Roche Composicion farmaceutica que comprende un inhibidor de lipasa y glucomanan.
US6746460B2 (en) 2002-08-07 2004-06-08 Satiety, Inc. Intra-gastric fastening devices
US7214233B2 (en) 2002-08-30 2007-05-08 Satiety, Inc. Methods and devices for maintaining a space occupying device in a relatively fixed location within a stomach
US7033384B2 (en) 2002-08-30 2006-04-25 Satiety, Inc. Stented anchoring of gastric space-occupying devices
US20060100171A1 (en) * 2002-09-09 2006-05-11 Ekhart Peter F Branched alpha-glucans for weight management
US7220237B2 (en) 2002-10-23 2007-05-22 Satiety, Inc. Method and device for use in endoscopic organ procedures
DK2368553T3 (en) 2003-04-08 2015-02-09 Progenics Pharm Inc Pharmaceutical preparation comprising methylnaltrexone
US7175638B2 (en) 2003-04-16 2007-02-13 Satiety, Inc. Method and devices for modifying the function of a body organ
US7914543B2 (en) 2003-10-14 2011-03-29 Satiety, Inc. Single fold device for tissue fixation
US7097650B2 (en) * 2003-10-14 2006-08-29 Satiety, Inc. System for tissue approximation and fixation
US7628908B2 (en) * 2003-12-19 2009-12-08 Shell Oil Company Systems, methods, and catalysts for producing a crude product
US20050177176A1 (en) 2004-02-05 2005-08-11 Craig Gerbi Single-fold system for tissue approximation and fixation
WO2005079673A2 (en) 2004-02-13 2005-09-01 Satiety, Inc. Methods for reducing hollow organ volume
CA2547934C (en) * 2004-02-19 2013-05-21 Abbott Laboratories Methods of using gamma cyclodextrin to control blood glucose and insulin secretion
AU2005218318A1 (en) 2004-02-27 2005-09-15 Ethicon Endo-Surgery, Inc Methods and devices for reducing hollow organ volume
US8252009B2 (en) 2004-03-09 2012-08-28 Ethicon Endo-Surgery, Inc. Devices and methods for placement of partitions within a hollow body organ
US8628547B2 (en) 2004-03-09 2014-01-14 Ethicon Endo-Surgery, Inc. Devices and methods for placement of partitions within a hollow body organ
US9028511B2 (en) 2004-03-09 2015-05-12 Ethicon Endo-Surgery, Inc. Devices and methods for placement of partitions within a hollow body organ
US8449560B2 (en) 2004-03-09 2013-05-28 Satiety, Inc. Devices and methods for placement of partitions within a hollow body organ
WO2005097012A2 (en) 2004-03-26 2005-10-20 Satiety, Inc. Systems and methods for treating obesity
US20050276781A1 (en) * 2004-06-09 2005-12-15 Ross Edward A Molecularly imprinted phosphate binders for therapeutic use
WO2006035296A1 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Process for the preparation of an orlistat derivative useful as reference standard in the determination of the purity of orlistat and process for the preparation of orlistat
US20060106288A1 (en) 2004-11-17 2006-05-18 Roth Alex T Remote tissue retraction device
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CN101171010B (zh) * 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
EP1897558B1 (en) * 2005-06-09 2013-09-04 Norgine BV Solid preparation of 2-hexadecyloxy-6-methyl-4h-3,1-benzoxazin-4-one
US20090209613A1 (en) * 2005-06-13 2009-08-20 Yeda Researc And Development Co. Ltd. At The Weizmann Institute Of Science Use of allymercaptocaptopril for treating or preventing obesity and obesity related diseases
AR056499A1 (es) * 2005-09-06 2007-10-10 Serapis Farmaceuticals Ltd Compuestos
AR060690A1 (es) * 2005-11-08 2008-07-10 Genzyme Corp Polimeros que contienen magnesio para la hiperfosfatemia
AU2006325820B2 (en) * 2005-12-12 2013-02-14 Allaccem, Inc. Methods and systems for preparing antimicrobial films and coatings
EP1803714A1 (en) * 2005-12-27 2007-07-04 KRKA, tovarna zdravil, d.d., Novo mesto Process for preparing crystalline forms of orlistat
CA2637950A1 (en) * 2006-01-25 2007-08-02 Yeda Research And Development Co. Ltd. A process for preparing allylmercaptocaptopril (cpssa) and related asymmetrical disulfides
US7749536B2 (en) * 2006-02-14 2010-07-06 Teva Pharmaceutical Industries Ltd. Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture
PL1818048T3 (pl) * 2006-02-14 2009-06-30 Teva Pharma Formulacje farmaceutyczne zawierające polimery amin alifatycznych oraz sposoby ich wytwarzania
BRPI0717008A2 (pt) 2006-09-01 2014-01-21 Usv Ltd Processo para o preparo de cloridrato de sevelamer e formulação do mesmo
US7964182B2 (en) * 2006-09-01 2011-06-21 USV, Ltd Pharmaceutical compositions comprising phosphate-binding polymer
US20080069906A1 (en) * 2006-09-18 2008-03-20 Thompson Ronald J Method and composition of a carminative herb or natural supplement to decrease the adverse effects of orlistat, and oral lipase inhibitor
US7662373B2 (en) * 2006-09-18 2010-02-16 Thompson Ronald J Method and composition of a medicament to decrease the adverse events of Olistat, an oral lipase inhibitor
GB0618725D0 (en) * 2006-09-23 2006-11-01 Jagotec Ag Composition containing inhibitors of gastro-intestinal lipase
WO2008070308A2 (en) * 2006-10-24 2008-06-12 Thompson Md Ronald J Method and composition of a carminative herb or natural supplement to decrease the adverse effects of orlistat, an oral lipase inhibitor, and a method with formulations to concurrently reduce fracture risk and insure appropriate fatsoluble vitamin supplementation when using orlistat, an oral lipase inhibitor, and a method o
HUE046465T2 (hu) * 2006-12-22 2020-03-30 Ironwood Pharmaceuticals Inc Epesavat megkötõ anyagokat tartalmazó készítmények nyelõcsõ-rendellenességek kezelésére
EP1944025A1 (en) * 2007-01-09 2008-07-16 Ranbaxy Laboratories Limited Stable pharmaceutical compositions of orlistat
CA2683383C (en) 2007-02-21 2016-01-05 Allaccem, Incorporated Bridged polycyclic compound based compositions for the inhibition and amelioration of disease
HUE025662T2 (en) 2007-03-29 2016-04-28 Wyeth Llc Peripheral opioid receptor and antagonists and their uses
CA2865389A1 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms and uses thereof
TWI553009B (zh) 2007-03-29 2016-10-11 普吉尼製藥公司 末梢性類鴉片受體拮抗劑及其用途
US20090023682A1 (en) * 2007-07-19 2009-01-22 Joseph Artiss Composition Comprising Dietary Fat Complexer and Methods of Using Same
US8153618B2 (en) * 2007-08-10 2012-04-10 Allaccem, Inc. Bridged polycyclic compound based compositions for topical applications for pets
US8153617B2 (en) * 2007-08-10 2012-04-10 Allaccem, Inc. Bridged polycyclic compound based compositions for coating oral surfaces in humans
US8188068B2 (en) * 2007-08-10 2012-05-29 Allaccem, Inc. Bridged polycyclic compound based compositions for coating oral surfaces in pets
US20090074833A1 (en) * 2007-08-17 2009-03-19 Whiteford Jeffery A Bridged polycyclic compound based compositions for controlling bone resorption
EP2219614A1 (en) * 2007-10-15 2010-08-25 Inventis DDS Pvt Limited Pharmaceutical composition of orlistat
EP2240489A1 (en) 2008-02-06 2010-10-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
US20100016270A1 (en) * 2008-06-20 2010-01-21 Whiteford Jeffery A Bridged polycyclic compound based compositions for controlling cholesterol levels
US20100004218A1 (en) * 2008-06-20 2010-01-07 Whiteford Jeffery A Bridged polycyclic compound based compositions for renal therapy
WO2010041268A2 (en) * 2008-09-02 2010-04-15 Usv Limited Crosslinked polymers
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
CN102316872B (zh) 2008-11-26 2016-12-21 萨蒂奥根制药公司 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂
GB0900350D0 (en) * 2009-01-09 2009-02-11 Cambridge Entpr Ltd Formulations of viable bacteria for oral delivery
WO2010093243A1 (en) 2009-02-12 2010-08-19 Coöperatieve Mirzorg U.A., Arnhem Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
US20100330175A1 (en) * 2009-06-24 2010-12-30 Jobdevairakkam Christopher N Cross-linked polyallylamine tablet core
US20110152204A1 (en) * 2009-12-18 2011-06-23 Satiogen Pharmaceuticals, Inc. Treatment of Obesity or Diabetes with Bile Acid Sequestrants
ES2552657T3 (es) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
PL3400944T3 (pl) 2010-11-08 2020-11-16 Albireo Ab Inhibitory ibat w leczeniu chorób wątroby
US11154559B2 (en) 2011-09-29 2021-10-26 Ethicon Endo-Surgery, Inc. Methods and compositions of bile acids
WO2013063512A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
EP2591768B1 (en) * 2011-11-14 2014-07-16 Deva Holding Anonim Sirketi Single unit dosage formulations of sevelamer and fat soluble vitamins and surface active agents
JP2013147488A (ja) * 2011-12-21 2013-08-01 Taisho Pharmaceutical Co Ltd 固形製剤
GB201122213D0 (en) * 2011-12-23 2012-02-01 Norgine Bv Compositions
US8252312B1 (en) * 2011-12-27 2012-08-28 David Wong Oral solid composition comprising a lipid absorption inhibitor
WO2014072363A1 (en) 2012-11-06 2014-05-15 Nanologica Ab A porous silica material for use as a pharmaceutical or dietary active ingredient
CA2895357C (en) 2012-12-21 2020-01-07 National Health Research Institutes Mesoporous silica nanoparticles for oil absorption
RU2552926C1 (ru) * 2014-06-23 2015-06-10 Общество с ограниченной ответственностью "ПРОМОМЕД" Фармацевтическая комбинация для лечения и/или предупреждения нарушений, связанных с избыточным весом и/или ожирением, и способ лечения на ее основе
US10709755B2 (en) 2014-06-25 2020-07-14 Elobix Ab Solid formulation and method for preventing or reducing coloration thereof
US10743813B2 (en) 2014-09-11 2020-08-18 Rattan Nath Diabetes control using postprandial feedback
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
EP3413875B1 (en) * 2016-02-09 2020-01-29 Albireo AB Cholestyramine pellets and methods for preparation thereof
WO2019032026A1 (en) 2017-08-09 2019-02-14 Albireo Ab CHOLESTYRAMINE GRANULES, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
US11389545B2 (en) * 2018-01-09 2022-07-19 Aqua Regenerative Therapies Llc Bioactive nanoparticles and methods for making same
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
PE20210136A1 (es) 2018-06-20 2021-01-21 Albireo Ab Formulacion farmaceutica de odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
CN108685848B (zh) * 2018-08-13 2020-09-01 中山万汉制药有限公司 一种奥利司他口服乳剂及其制备方法
NL2022615B1 (en) 2019-02-21 2020-08-31 Patrick Alexander Unger Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
CN111297826B (zh) * 2020-04-20 2021-08-03 鲁南制药集团股份有限公司 一种稳定的奥利司他胶囊及其制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692895A (en) * 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
IT1052819B (it) * 1975-12-12 1981-07-20 Fargal Pharmasint Lab Biochim Preparato inibitore dell assorbimento dei lipidi a base di dietilamminoetildestrano
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
DE3414609C1 (de) * 1984-04-18 1985-06-20 Daimler-Benz Ag, 7000 Stuttgart Vorrichtung zur Beeinflussung eines Kuehlluftstromes
IT1190349B (it) * 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
US5063210A (en) * 1989-04-20 1991-11-05 Lange Iii Louis G Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption
US5344453A (en) * 1991-05-30 1994-09-06 Boston Medical Products, Inc. Thyroplasty implant
US5616570A (en) * 1991-10-18 1997-04-01 Lange, Iii; Louis G. Use of non-absorbable synthetic sulfated polysaccharides to decrease cholesterol absorbtion
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
US5607669A (en) * 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
TW381025B (en) * 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5569452A (en) * 1993-08-31 1996-10-29 Tsrl, Inc. Pharmaceutical formulation having enhanced bile acid binding affinity
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5545414A (en) * 1995-03-22 1996-08-13 Abbott Laboratories Cholesterol lowering food product
JP3832871B2 (ja) * 1995-04-03 2006-10-11 日本製粉株式会社 リパーゼ阻害剤
DK0815857T3 (da) 1995-12-26 2005-01-24 Suntory Ltd Anti-adipöst middel indeholdende procyanidin som den aktive ingrediens
US5612026A (en) * 1996-01-25 1997-03-18 The Procter & Gamble Company Cholesterol lowering drink mix compositons
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
JP3807464B2 (ja) 1997-11-17 2006-08-09 康二 嘉島 肥満防止剤
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
BR9907234A (pt) 1998-01-09 2000-10-10 Geltex Pharma Inc Polìmeros ligantes de gordura
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
FI113356B (fi) 1998-05-20 2004-04-15 Upm Kymmene Corp Pakkauksenmuodostuslaite
KR20010079635A (ko) * 1998-08-14 2001-08-22 프리돌린 클라우스너, 롤란드 비. 보레르 리파아제 저해제를 함유하는 약학 조성물
DE69916288T2 (de) * 1998-08-14 2005-03-24 F. Hoffmann-La Roche Ag Lipasehemmer und chitosan enthaltende arzneimittel
WO2000013667A1 (en) 1998-09-08 2000-03-16 Smithkline Beecham Corporation Lipstatin derivative-soluble fiber tablets
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
CA2360065A1 (en) 1999-01-22 2000-07-27 Hunza Di Maria Carmela Marazzita S.A.S. Lipoprotein complexes and compositions containing them
AR025609A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
EP1307264B1 (en) * 2000-07-28 2004-10-20 F. Hoffmann-La Roche Ag New pharmaceutical composition

Also Published As

Publication number Publication date
US8071571B2 (en) 2011-12-06
HU229292B1 (en) 2013-10-28
ZA200300456B (en) 2004-04-16
GT200100152A (es) 2002-05-16
IL154008A (en) 2011-12-29
JP4265911B2 (ja) 2009-05-20
BR0112799B1 (pt) 2017-10-24
EG24357A (en) 2009-03-04
CN100423715C (zh) 2008-10-08
CA2416901C (en) 2007-07-03
NO20030418D0 (no) 2003-01-27
PA8523201A1 (es) 2002-10-24
SI1307264T1 (en) 2005-02-28
HK1058636A1 (en) 2004-05-28
HRP20030029A2 (en) 2004-02-29
MY127247A (en) 2006-11-30
PT1307264E (pt) 2005-02-28
US6756364B2 (en) 2004-06-29
WO2002009815A2 (en) 2002-02-07
US20040105838A1 (en) 2004-06-03
WO2002009815A3 (en) 2002-04-18
MEP90508A (en) 2011-12-20
ES2230362T3 (es) 2005-05-01
UY26860A1 (es) 2002-01-31
EP1307264B1 (en) 2004-10-20
CZ302087B6 (cs) 2010-10-06
RU2241462C2 (ru) 2004-12-10
PL204443B1 (pl) 2010-01-29
ME00671B (me) 2011-12-20
JO2320B1 (en) 2005-09-12
DE60106623D1 (de) 2004-11-25
CZ2003582A3 (cs) 2004-02-18
NO330546B1 (no) 2011-05-16
HRP20030029B1 (en) 2005-06-30
IL154008A0 (en) 2003-07-31
US20100203032A1 (en) 2010-08-12
US20020035089A1 (en) 2002-03-21
KR20030029796A (ko) 2003-04-16
KR100572785B1 (ko) 2006-04-19
JP2004505067A (ja) 2004-02-19
US20050136030A1 (en) 2005-06-23
MA26937A1 (fr) 2004-12-20
MXPA03000771A (es) 2003-06-04
PE20020336A1 (es) 2002-05-08
JP2009073833A (ja) 2009-04-09
CN1444495A (zh) 2003-09-24
DE60106623T2 (de) 2006-02-02
AR033548A1 (es) 2003-12-26
HUP0301281A2 (hu) 2003-08-28
YU5003A (sh) 2006-01-16
TWI275395B (en) 2007-03-11
HUP0301281A3 (en) 2005-05-30
AU2001289699B2 (en) 2006-06-01
AU8969901A (en) 2002-02-13
ECSP034450A (es) 2003-03-10
NO20030418L (no) 2003-01-27
ATE279961T1 (de) 2004-11-15
PL366105A1 (en) 2005-01-24
US20060269510A1 (en) 2006-11-30
CA2416901A1 (en) 2002-02-07
NZ523684A (en) 2005-04-29
EP1307264A2 (en) 2003-05-07
BR0112799A (pt) 2003-07-01

Similar Documents

Publication Publication Date Title
RS50397B (sr) Farmaceutska smeša
ATE306251T1 (de) Verwendung eines biologisch abbaubaren polymers
ATE346039T1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
TR200302105T4 (tr) Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları.
RS50031B (sr) Triciklični inhibitori poli(adp-riboza)polimeraza
ATE264348T1 (de) Bioadhesive zusammensetzungen aus polymeren
CY1110988T1 (el) Ταχεως αποσαθρουμενο στερεο παρασκευασμα
CA2216796A1 (en) Quinazoline derivatives
DK1276470T3 (da) Smagskaskerende overtrækssammensætning
ATE243711T1 (de) Aggregate von menschlichen insulinderivaten
HRP20010277B1 (en) Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose derivative
PT1152662E (pt) Utilizacao da 3-(2,4,6-trimetilfenil)-4-neopentilcarboniloxi-5,5-tetrametileno-delta3-di-hidrofuran-2-ona no combate a mosca branca
RS50348B (sr) Farmaceutski oblik dronedarona za parenteralnu upotrebu
BR0308710A (pt) conjugados poliméricos antimicrobianos
ATE268175T1 (de) Decursin-enthaltende pharmazeutische zusammensetzungen
HUP0203226A2 (hu) Hatóanyagként benzamidszármazékot tartalmazó gyógyszerkészítmény
WO2002040001A3 (en) Compositions for treatment of malignant effusions comprising a biocompatible polymer and antineoplastic taxane
HRP20010764B1 (en) Prucalopride oral solution
AU2001294790A1 (en) Method of achieving overnight laxation and control of bowel function
BR9805437A (pt) Derivados de benzocicloalquenos heterocìclicos, processo para fabricação de derivados de benzocicloalquenos heterocìclicos e uso de derivados de benzocicloalquenos heterocìclicos.
CA2399709A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
EP1085072A3 (de) Emissionsarmer, biologisch abbaubarer Klebstoff
ES2187271A1 (es) Combinaciones de polimeros de almidon usados en la fabricacion de papel.
WO2003031467A3 (en) Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament
PT1203121E (pt) Agente de retencao de agua soluvel em agua